

Oana Ciofu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/310240/publications.pdf>

Version: 2024-02-01

102
papers

13,019
citations

44069

48
h-index

37204

96
g-index

106
all docs

106
docs citations

106
times ranked

13304
citing authors

#	ARTICLE	IF	CITATIONS
1	Tolerance and resistance of microbial biofilms. <i>Nature Reviews Microbiology</i> , 2022, 20, 621-635.	28.6	316
2	Polymicrobial infections can select against <i>Pseudomonas aeruginosa</i> mutators because of quorum-sensing trade-offs. <i>Nature Ecology and Evolution</i> , 2022, 6, 979-988.	7.8	10
3	Adjunctive S100A8/A9 Immunomodulation Hinders Ciprofloxacin Resistance in <i>Pseudomonas aeruginosa</i> in a Murine Biofilm Wound Model. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 652012.	3.9	4
4	The evolutionary trajectories of <i>P. aeruginosa</i> in biofilm and planktonic growth modes exposed to ciprofloxacin: beyond selection of antibiotic resistance. <i>Npj Biofilms and Microbiomes</i> , 2020, 6, 28.	6.4	29
5	A systematic Cochrane Review of antioxidant supplementation lung disease for cystic fibrosis. <i>Paediatric Respiratory Reviews</i> , 2020, 33, 28-29.	1.8	3
6	Lack of the Major Multifunctional Catalase KatA in <i>Pseudomonas aeruginosa</i> Accelerates Evolution of Antibiotic Resistance in Ciprofloxacin-Treated Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	12
7	P124 Effect of ceftazidime-avibactam on biofilm of AmpC hyperproducers <i>Pseudomonas aeruginosa</i> . <i>Journal of Cystic Fibrosis</i> , 2019, 18, S92.	0.7	0
8	Tolerance and Resistance of <i>Pseudomonas aeruginosa</i> Biofilms to Antimicrobial Agents—How <i>P. aeruginosa</i> Can Escape Antibiotics. <i>Frontiers in Microbiology</i> , 2019, 10, 913.	3.5	428
9	Antibiotic therapy as personalized medicine – general considerations and complicating factors. <i>Apmis</i> , 2019, 127, 361-371.	2.0	44
10	<i>P. aeruginosa</i> flow-cell biofilms are enhanced by repeated phage treatments but can be eradicated by phage–ciprofloxacin combination. <i>Pathogens and Disease</i> , 2019, 77, .	2.0	50
11	Improving antibiotic treatment of bacterial biofilm by hyperbaric oxygen therapy: Not just hot air. <i>Biofilm</i> , 2019, 1, 100008.	3.8	28
12	Antioxidant supplementation for lung disease in cystic fibrosis. <i>The Cochrane Library</i> , 2019, 2019, CD007020.	2.8	19
13	Formation of <i>Pseudomonas aeruginosa</i> inhibition zone during tobramycin disk diffusion is due to transition from planktonic to biofilm mode of growth. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 564-573.	2.5	33
14	Hyperbaric oxygen treatment increases killing of aggregating <i>Pseudomonas aeruginosa</i> isolates from cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2019, 18, 657-664.	0.7	24
15	IgG avidity to <i>Pseudomonas aeruginosa</i> over the course of chronic lung biofilm infection in cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 356-359.	0.7	5
16	Adaptation of <i>Pseudomonas aeruginosa</i> to the chronic phenotype by mutations in the <i>algTmucABD</i> operon in isolates from Brazilian cystic fibrosis patients. <i>PLoS ONE</i> , 2018, 13, e0208013.	2.5	24
17	Evolution of Antibiotic Resistance in Biofilm and Planktonic <i>Pseudomonas aeruginosa</i> Populations Exposed to Subinhibitory Levels of Ciprofloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	97
18	P044 Azithromycin resistance develops fast in <i>P. aeruginosa</i> but has no negative impact on lung function development in CF patients with chronic infection. <i>Journal of Cystic Fibrosis</i> , 2018, 17, S71.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Diagnosis of biofilm infections in cystic fibrosis patients. <i>Apmis</i> , 2017, 125, 339-343.	2.0	69
20	Antibiotic treatment of biofilm infections. <i>Apmis</i> , 2017, 125, 304-319.	2.0	299
21	Real-Time Monitoring of <i>Pseudomonas aeruginosa</i> Mutant Occurrence and Dynamics in <i>Pseudomonas aeruginosa</i> Biofilm Exposed to Subinhibitory Concentrations of Ciprofloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	29
22	Hyperbaric Oxygen Sensitizes Anoxic <i>Pseudomonas aeruginosa</i> Biofilm to Ciprofloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	44
23	Detection of multidrug-resistant bacteria in the occupied Palestinian territory: a cross-sectional study. <i>Lancet, The</i> , 2017, 390, S12.	13.7	1
24	Phenotypic shift in <i>Pseudomonas aeruginosa</i> populations from cystic fibrosis lungs after 2-week antipseudomonal treatment. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 222-229.	0.7	36
25	Genome Sequence of <i>Pseudomonas aeruginosa</i> Strain DK1-NH57388A, a Stable Mucoïd Cystic Fibrosis Isolate. <i>Genome Announcements</i> , 2016, 4, .	0.8	11
26	Proteome-wide antigen discovery of novel protective vaccine candidates against <i>Staphylococcus aureus</i> infection. <i>Vaccine</i> , 2016, 34, 4602-4609.	3.8	6
27	WS01.5 Effect of hyperbaric oxygen treatment on anoxic <i>P. aeruginosa</i> biofilm killing by ciprofloxacin. <i>Journal of Cystic Fibrosis</i> , 2016, 15, S2.	0.7	0
28	Reinforcement of the bactericidal effect of ciprofloxacin on <i>Pseudomonas aeruginosa</i> biofilm by hyperbaric oxygen treatment. <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 163-167.	2.5	68
29	OligoG CF-5/20 Disruption of Mucoïd <i>Pseudomonas aeruginosa</i> Biofilm in a Murine Lung Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2620-2626.	3.2	52
30	Increased bactericidal activity of colistin on <i>Pseudomonas aeruginosa</i> biofilms in anaerobic conditions. <i>Pathogens and Disease</i> , 2016, 74, ftv086.	2.0	34
31	The phenotypic evolution of <i>Pseudomonas aeruginosa</i> populations changes in the presence of subinhibitory concentrations of ciprofloxacin. <i>Microbiology (United Kingdom)</i> , 2016, 162, 865-875.	1.8	30
32	Chronic Infection with <i>Pseudomonas aeruginosa</i> in an Animal Model of Oxidative Stress. , 2015, , 171-178.		0
33	Within-host microevolution of <i>Pseudomonas aeruginosa</i> in Italian cystic fibrosis patients. <i>BMC Microbiology</i> , 2015, 15, 218.	3.3	62
34	The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic <i>P. aeruginosa</i> infection – A pilot study. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 211-218.	0.7	31
35	WS02.5 Pharmacodynamics of ceftazidime combined with β -lactamase inhibitors in biofilm <i>Pseudomonas aeruginosa</i> in vitro. <i>Journal of Cystic Fibrosis</i> , 2015, 14, S4.	0.7	1
36	Diversity of metabolic profiles of cystic fibrosis <i>Pseudomonas aeruginosa</i> during the early stages of lung infection. <i>Microbiology (United Kingdom)</i> , 2015, 161, 1447-1462.	1.8	27

#	ARTICLE	IF	CITATIONS
37	Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. <i>Advanced Drug Delivery Reviews</i> , 2015, 85, 7-23.	13.7	250
38	Physiological levels of nitrate support anoxic growth by denitrification of <i>Pseudomonas aeruginosa</i> at growth rates reported in cystic fibrosis lungs and sputum. <i>Frontiers in Microbiology</i> , 2014, 5, 554.	3.5	68
39	Detection of NDM-2-producing <i>Acinetobacter baumannii</i> and VIM-producing <i>Pseudomonas aeruginosa</i> in Palestine. <i>Journal of Global Antimicrobial Resistance</i> , 2014, 2, 93-97.	2.2	13
40	Pharmacokinetics and Pharmacodynamics of Antibiotics in Biofilm Infections of <i>Pseudomonas aeruginosa</i> In Vitro and In Vivo. <i>Methods in Molecular Biology</i> , 2014, 1147, 239-254.	0.9	22
41	Formation of hydroxyl radicals contributes to the bactericidal activity of ciprofloxacin against <i>Pseudomonas aeruginosa</i> biofilms. <i>Pathogens and Disease</i> , 2014, 70, 440-443.	2.0	76
42	Bactericidal effect of colistin on planktonic <i>Pseudomonas aeruginosa</i> is independent of hydroxyl radical formation. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 140-147.	2.5	56
43	Antioxidant supplementation for lung disease in cystic fibrosis. <i>The Cochrane Library</i> , 2014, , CD007020.	2.8	36
44	Applying insights from biofilm biology to drug development – can a new approach be developed?. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 791-808.	46.4	421
45	<i>P. aeruginosa</i> in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 729-736.	0.7	69
46	Sublethal Ciprofloxacin Treatment Leads to Rapid Development of High-Level Ciprofloxacin Resistance during Long-Term Experimental Evolution of <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4215-4221.	3.2	103
47	Respiratory bacterial infections in cystic fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , 2013, 19, 251-258.	2.6	167
48	High β -Lactamase Levels Change the Pharmacodynamics of β -Lactam Antibiotics in <i>Pseudomonas aeruginosa</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 196-204.	3.2	69
49	Complete Genome Sequence of the Cystic Fibrosis Pathogen <i>Achromobacter xylosoxidans</i> NH44784-1996 Complies with Important Pathogenic Phenotypes. <i>PLoS ONE</i> , 2013, 8, e68484.	2.5	85
50	Effect of Long-Term Voluntary Exercise Wheel Running on Susceptibility to Bacterial Pulmonary Infections in a Mouse Model. <i>PLoS ONE</i> , 2013, 8, e82869.	2.5	7
51	Evolution and diversification of <i>Pseudomonas aeruginosa</i> in the paranasal sinuses of cystic fibrosis children have implications for chronic lung infection. <i>ISME Journal</i> , 2012, 6, 31-45.	9.8	184
52	Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of <i>Pseudomonas aeruginosa</i> biofilm infections. <i>FEMS Immunology and Medical Microbiology</i> , 2012, 66, 120-120.	2.7	2
53	Initial <i>Pseudomonas aeruginosa</i> infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. <i>Clinical Microbiology and Infection</i> , 2012, 18, 567-574.	6.0	37
54	A complex multilevel attack on <i>Pseudomonas aeruginosa</i> algT/U expression and AlgT/U activity results in the loss of alginate production. <i>Gene</i> , 2012, 498, 242-253.	2.2	35

#	ARTICLE	IF	CITATIONS
55	Adaptation of <i>Pseudomonas aeruginosa</i> to the cystic fibrosis airway: an evolutionary perspective. <i>Nature Reviews Microbiology</i> , 2012, 10, 841-851.	28.6	635
56	Molecular Epidemiology of Chronic <i>Pseudomonas aeruginosa</i> Airway Infections in Cystic Fibrosis. <i>PLoS ONE</i> , 2012, 7, e50731.	2.5	61
57	<i>In Vivo</i> Pharmacokinetics/Pharmacodynamics of Colistin and Imipenem in <i>Pseudomonas aeruginosa</i> Biofilm Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2683-2690.	3.2	164
58	Poor Antioxidant Status Exacerbates Oxidative Stress and Inflammatory Response to <i>Pseudomonas aeruginosa</i> Lung Infection in Guinea Pigs. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 110, 353-358.	2.5	15
59	Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of <i>Pseudomonas aeruginosa</i> biofilm infections. <i>FEMS Immunology and Medical Microbiology</i> , 2012, 65, 215-225.	2.7	84
60	Development of antibiotic resistance and up-regulation of the antimutator gene <i>pfpl</i> in mutator <i>Pseudomonas aeruginosa</i> due to inactivation of two DNA oxidative repair genes (<i>mutY</i> , <i>mutM</i>). <i>FEMS Microbiology Letters</i> , 2011, 324, 28-37.	1.8	18
61	Mucoid <i>Pseudomonas aeruginosa</i> isolates maintain the biofilm formation capacity and the gene expression profiles during the chronic lung infection of CF patients. <i>Apmis</i> , 2011, 119, 263-274.	2.0	47
62	The clinical impact of bacterial biofilms. <i>International Journal of Oral Science</i> , 2011, 3, 55-65.	8.6	663
63	Pharmacokinetics/Pharmacodynamics of Colistin and Imipenem on Mucoid and Nonmucoid <i>Pseudomonas aeruginosa</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4469-4474.	3.2	179
64	Evolutionary dynamics of bacteria in a human host environment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 7481-7486.	7.1	327
65	<i>Pseudomonas aeruginosa</i> Biofilms in the Lungs of Cystic Fibrosis Patients. , 2011, , 167-184.		3
66	Cellular responses of A549 alveolar epithelial cells to serially collected <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients at different stages of pulmonary infection. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 59, 207-220.	2.7	44
67	Genetic adaptation of <i>Pseudomonas aeruginosa</i> during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in <i>muA</i> and/or <i>lasR</i> mutants. <i>Microbiology (United Kingdom)</i> , 2010, 156, 1108-1119.	1.8	171
68	Polymorphonuclear leucocytes consume oxygen in sputum from chronic <i>Pseudomonas aeruginosa</i> pneumonia in cystic fibrosis. <i>Thorax</i> , 2010, 65, 57-62.	5.6	167
69	<i>Pseudomonas aeruginosa</i> biofilms in cystic fibrosis. <i>Future Microbiology</i> , 2010, 5, 1663-1674.	2.0	557
70	Antibiotic resistance of bacterial biofilms. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 322-332.	2.5	2,809
71	Quorum Sensing and Virulence of <i>Pseudomonas aeruginosa</i> during Lung Infection of Cystic Fibrosis Patients. <i>PLoS ONE</i> , 2010, 5, e10115.	2.5	217
72	Antibiotic Tolerance and Resistance in Biofilms. , 2010, , 215-229.		17

#	ARTICLE	IF	CITATIONS
73	Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 1241-1250.	3.0	21
74	Antibiotic Resistance in <i>Pseudomonas aeruginosa</i> Strains with Increased Mutation Frequency Due to Inactivation of the DNA Oxidative Repair System. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 2483-2491.	3.2	90
75	Respiratory syncytial virus infection facilitates acute colonization of <i>Pseudomonas aeruginosa</i> in mice. <i>Journal of Medical Virology</i> , 2009, 81, 2096-2103.	5.0	41
76	Novel experimental <i>Pseudomonas aeruginosa</i> lung infection model mimicking long-term host-pathogen interactions in cystic fibrosis. <i>Apmis</i> , 2009, 117, 95-107.	2.0	47
77	Chromosomal mechanisms of aminoglycoside resistance in <i>Pseudomonas aeruginosa</i> isolates from cystic fibrosis patients. <i>Clinical Microbiology and Infection</i> , 2009, 15, 60-66.	6.0	74
78	Spread of colistin resistant non-mucoid <i>Pseudomonas aeruginosa</i> among chronically infected Danish cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2008, 7, 391-397.	0.7	141
79	Maximum Likelihood based comparison of the specific growth rates for <i>P. aeruginosa</i> and four mutator strains. <i>Journal of Microbiological Methods</i> , 2008, 75, 551-557.	1.6	3
80	Investigation of the <i>algT</i> operon sequence in mucoid and non-mucoid <i>Pseudomonas aeruginosa</i> isolates from 115 Scandinavian patients with cystic fibrosis and in 88 in vitro non-mucoid revertants. <i>Microbiology (United Kingdom)</i> , 2008, 154, 103-113.	1.8	77
81	Cystic Fibrosis "Coping with Resistance." , 2008, , 149-174.		2
82	Molecular Epidemiology and Dynamics of <i>Pseudomonas aeruginosa</i> Populations in Lungs of Cystic Fibrosis Patients. <i>Infection and Immunity</i> , 2007, 75, 2214-2224.	2.2	220
83	Heterogeneity of Biofilms Formed by Nonmucoid <i>Pseudomonas aeruginosa</i> Isolates from Patients with Cystic Fibrosis. <i>Journal of Clinical Microbiology</i> , 2005, 43, 5247-5255.	3.9	142
84	Novel Mouse Model of Chronic <i>Pseudomonas aeruginosa</i> Lung Infection Mimicking Cystic Fibrosis. <i>Infection and Immunity</i> , 2005, 73, 2504-2514.	2.2	158
85	Occurrence of Hypermutable <i>Pseudomonas aeruginosa</i> in Cystic Fibrosis Patients Is Associated with the Oxidative Stress Caused by Chronic Lung Inflammation. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2276-2282.	3.2	232
86	Immunisation in the current management of cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2005, 4, 77-87.	0.7	61
87	Dynamics and Spatial Distribution of β -Lactamase Expression in <i>Pseudomonas aeruginosa</i> Biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1168-1174.	3.2	165
88	<i>Pseudomonas aeruginosa</i> Biofilms Exposed to Imipenem Exhibit Changes in Global Gene Expression and β -Lactamase and Alginate Production. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1175-1187.	3.2	302
89	<i>Pseudomonas aeruginosa</i> alginate is refractory to Th1 immune response and impedes host immune clearance in a mouse model of acute lung infection. <i>Journal of Medical Microbiology</i> , 2003, 52, 731-740.	1.8	76
90	<i>Pseudomonas aeruginosa</i> chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. <i>Acta Pathologica Microbiologica Et Immunologica Scandinavica - Supplementum</i> , 2003, , 1-47.	0.2	6

#	ARTICLE	IF	CITATIONS
91	Constitutive High Expression of Chromosomal $\hat{\beta}$ -Lactamase in <i>Pseudomonas aeruginosa</i> Caused by a New Insertion Sequence (IS 1669) Located in ampD. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3406-3411.	3.2	114
92	Antibodies against beta-lactamase can improve ceftazidime treatment of lung infection with beta-lactam-resistant <i>Pseudomonas aeruginosa</i> in a rat model of chronic lung infection. <i>Apmis</i> , 2002, 110, 881-891.	2.0	30
93	Characterization of paired mucoid/non-mucoid <i>Pseudomonas aeruginosa</i> isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. <i>Journal of Antimicrobial Chemotherapy</i> , 2001, 48, 391-396.	3.0	77
94	Typing of <i>Pseudomonas aeruginosa</i> strains in Norwegian cystic fibrosis patients. <i>Clinical Microbiology and Infection</i> , 2001, 7, 238-243.	6.0	40
95	and the in vitro and in vivo biofilm mode of growth. <i>Microbes and Infection</i> , 2001, 3, 23-35.	1.9	339
96	Rapid development in vitro and in vivo of resistance to ceftazidime in biofilm-growing <i>Pseudomonas aeruginosa</i> due to chromosomal $\hat{\beta}$ -lactamase. <i>Apmis</i> , 2000, 108, 589-600.	2.0	55
97	Molecular Mechanisms of Fluoroquinolone Resistance in <i>Pseudomonas aeruginosa</i> Isolates from Cystic Fibrosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 710-712.	3.2	200
98	Mucoid conversion of <i>Pseudomonas aeruginosa</i> by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. <i>Microbiology (United Kingdom)</i> , 1999, 145, 1349-1357.	1.8	437
99	Meropenem in cystic fibrosis patients infected with resistant <i>Pseudomonas aeruginosa</i> or <i>Burkholderia cepacia</i> and with hypersensitivity to $\hat{\beta}$ -lactam antibiotics. <i>Clinical Microbiology and Infection</i> , 1996, 2, 91-98.	6.0	26
100	Use of carbapenems and other antibiotics for pulmonary infections in patients with cystic fibrosis. <i>Pediatric Infectious Disease Journal</i> , 1996, 15, 738-743.	2.0	13
101	Antibodies against <i>Pseudomonas aeruginosa</i> chromosomal $\hat{\beta}$ -lactamase in patients with cystic fibrosis are markers of the development of resistance of <i>P. aeruginosa</i> to $\hat{\beta}$ -lactams. <i>Journal of Antimicrobial Chemotherapy</i> , 1995, 35, 295-304.	3.0	10
102	<i>Pseudomonas</i> . , 0, , 773-790.		6